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Summary: The measurement of reactive oxygen species provides a simple method for monitoring the degree
of activation of leukocytes in various disorders, and for determining the effects of drugs on this activation.
The present report describes the determination of luminol- or lucigenin-amplified chemiluminescence of whole
blood in a microtitre plate assay with a 96-well luminometer (HAMAMATSU MTP reader®).
Using heparinized venous human blood from healthy donors, optimal chemiluminescence intensities were
determined at a blood dilution of 1/100 in a total volume of 0.25 ml of Hank's balanced salt solution,
containing 0.4mmol/l luminol as enhancer and either opsonized zymosan (1 g/1) or the phorbol ester, 12-O-
tetradecanoylphorbol 13-acetate (10~6mol/l), as stimuli. The in vitro effects of nordihydroguaiaretic acid,
diphenylene iodonium, and diclofenac were tested. After preincubation of the diluted whole blood with these
drugs for 15 min, the zymosan-stimulated chemiluminescence was diminished in all cases. The specific NADPH
oxidase inhibitor, diphenylene iodonium, was most effective (half maximal inhibition at 1.5 χ 10~8 mol/1),
whereas higher concentrations of the antioxidant, nordihydroguaiaretic acid (1.6 χ 10~6 mol/1), or the non-
steroidal antiinflammatory drug, diclofenac (about 10"5 mol/1), were needed to achieve half maximal inhibition.
In addition to its usefulness in the rapid screening of drug effects this assay system seems to be very beneficial
for the clinical diagnosis of congenital disorders. Furthermore, it is suited as an effective and simple method
for the continuous determination of the phagocyte functional state in patients in pathophysiological situations
and during therapy.
Introduction / . , , · , χ ·ι ι t t *. r
ence of hahde) contribute to the development of cy-
Reactive oxygen species such as the Superoxide anion to toxic and antimicrobial activities of activated phag-
radical (Oi~), hydroxyl radicals, hydrogen peroxide ocytes (1) and also play an important role in inflam-
(H2O2), and hypochlorous acid (generated by the mye- matory processes (2). Various methods for the meas-
loperoxidase-mediated conversion of H2O2in thepres- urement of reaction oxygen species have been estab-
lished (3). For example, Oi~ can be determined by the
Superoxide dismutase^-inhibitable reduction of cyto-
') Enzymes: ^ «« ^ chrome c or nitroblue tetrazolium salts (4) and H2O2Catalase (H2O2:H2O2 oxidoreductase, EC 1.11.1.6) , . . , - , , ,.. ι *· /c\Myeloperoxidase (myeloperoxidase, EC 1.11.1.7) by reaction with phenol red (4) or scopoletm (5).
NADPH oxidase (NADPH: O2-oxidoreductase) Reactive oxygen species decay is accompanied by the
Superoxide dismutase (superoxide: Superoxide oxidoreduc- emission of small amounts of light but this chemilu-
tase, EC 1.15.1.1) . .
 t . * , . ,Xanthine oxidase (xanthine: oxygen oxidoreductase, EC minescence is enormously intensified m the presence
1.1.3.22) of chemical amplifiers such as luminol or lucigenin
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(6). As this method is very simple, provided that a
suitable measuring instrument is available, the detec-
tion of chemiluminescence is used widely as a func-
tional quantity of polymorphonuclear leukocytes and
monocytic cells (7).
We (8) and others (9) have previously described an
assay system for the detection of enhanced chemilu-
minescence of isolated phagocytes in microtitre plates.
In this report we show that by using an even more
sensitive luminometer (10) the chemiluminescence of
diluted whole blood can also be evaluated in 96 sam-
ples monitored in parallel, using only micro-quantities
of human blood.
Materials and Methods
Materials
All assays are performed in white 96-well microtitre plates
(MicroFLUOR®, Dynatech, Denkendorf, Germany) using a
luminometer equipped with a sensitive single photon imaging
device (MTP reader®, Hamamatsu Photonics, Herrsching, Ger-
many). This system allows the continuous chemiluminescence
registration of all wells simultaneously. The chemical enhancers,
luminol (5/-amino-2,3-dihydro-l,4-phthalazinedione) and luci-
genin ([9,9'-bis-(N-methyl-acridinium nitrate)]), were obtained
from Boehringer, Mannheim, Germany, and stored at 4 °C as
10~2 mol/1 stock solutions in Hank's balanced salt solution
(Gibco, Eggenstein, Germany). When luminol was used, trieth-
anolamine (5 ml/1 Hank's balanced salt solution) was also added
to achieve solution. The stimuli, 12-O-tetradecanoylphorbol 13-
acetate (10~3 mol/1 stock solution in dimethylsulphoxide at
— 80 °C) and zymosan, were purchased from Sigma (Deisen-
hofen, Germany). Nordihydroguaiaretic acid (10~2 mol/1 stock
solution in ethanol at — 20 °C), diclofenac (10~3 mol/1 stock
solution in Hank's balanced salt solution in —20 °C), sodium
azide, Superoxide dismutase (from bovine erythrocytes, 3 kU/
mg protein), and catalase (from bovine liver, 44 kU/mg protein)
were also from Sigma. Diphenylene iodonium was kindly pro-
vided by Prof. O. T. G. Jones (Bristol, U. K.).
Methods
Venous blood was taken from healthy adults and coagulation
was prevented by addition of 10 · 103 U/l heparin (Liquemin®
N 25000, Hoffmann-La Roche, Grenzach-Wyhlen, Germany).
Leukocyte counts and the haemoglobin content were deter-
mined in the clinical routine laboratory by a Coulter® Counter
system.
After storage of the whole blood at room temperature for no
longer than two hours in polypropylene tubes, it was diluted
in Hank's balanced salt solution directly before the start of the
experiment.
Opsonized zymosan was prepared as follows. Zymosan (1 ml,
50 g/1) was boiled in phosphate-buffered saline for 90 min and
washed three times with phosphate buffered saline by centrif-
ugation (16000g, 10 min). The final pellet was resuspended in
20 ml pooled human serum and incubated for 30 min at 37 °C.
After washing with phosphate buffered saline, the opsonized
zymosan (10 g/1) was stored at — 20 °C. Chemiluminescence
measurements were performed in a total volume of 250 μΐ/well.
Whole blood (50 μΐ, diluted 1/20 with Hank's balanced salt
solution) was carefully mixed with enhancer (100 μΐ) and Hank's
balanced salt solution (75 μΐ) and preincubated for 30 min at
37 °C in the luminometer. After addition of the stimulus or
vehicle (25 μΐ) light emission was continuously recorded for 30
min. For the investigation of drug effects on reactive oxygen
species formation, nordihydroguaiaretic acid, diphenylene
iodonium, diclofenac, Superoxide dismutase, catalase, or so-
dium azide were included in the assay 15 min prior to the
stimulus addition.
Results
Optimization of assay conditions for whole
blood chemiluminescence measurement in
96-well microti tre plates
Experiments were first carried out to determine the
optimal assay conditions for whole blood chemilu-
minescence measurement in the 96-well luminometer.
The sensitivity of the assay largely depends on the
choice of a suitable chemical chemiluminescence en-
hancer. Figure 1 shows the effects of luminol and
lucigenin, respectively, on opsonized zymosan- or 12-
O-tetradecanoylphorbol 13-acetate-stimulated emis-
sion over 30 min from 1/100 diluted whole blood.
With both stimuli significantly higher total counts
were observed when luminol was included, showing
an optimum at a concentration of about 400 μηιοΐ/ΐ.
Lucigenin revealed its best enhancing effect on light
emission at lower concentrations (about 100 μηιοΐ/ΐ).
The stimulation of reactive oxygen species production
was more pronounced with opsonized zymosan than
with 12-O-tetradecanoylphorbol 13-acetate for both
enhancers. This holds true for total chemiluminesc-
ence recordings (fig. 1) as well as for the maximal
chemiluminescence intensities seen at about 10 min
after stimulus addition (data not shown). Therefore,
further experiments were performed solely in the pres-
ence of luminol.
Next we evaluated the dose-dependency" of the stimuli.
As can be seen in figure 2, the highest stimulatory
effects were observed using opsonized zymosan in
concentrations between 0.5 and 1.5 g/1, or 12-O-tetra-
decanoylphorbol 13-acetate at 10~6 to 10~5 mol/1.
Non-opsonized zymosan was about half as effective
as opsonized zymosan in its ability to induce reactive
oxygen species production (data not shown). Further
experiments were done in the presence of either op-
sonized zymosan (1 g/1) or 12-O-tetradecanoylphor-
bol 13-acetate (10~6 mol/1).
The most critical point in whole blood chemilumi-
nescence measurement is the dilution of the heparin-
ized whole blood, in order to reduce the concentra-
tions of substances that interfere with reactive oxygen
species production or quench light emission. Using
blood from healthy donors a distinct maximum of
light emission after stimulation with opsonized zym-
osan or 12-O-tetradecanoylphorbol 13-acetate was
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Fig. 1. Determination of the most suitable enhancer concentra-
tion for whole blood chemiluminescence. Blood (finally
diluted 1/100) was preincubated with luminol (fig. la)
or lucigenin (fig. Ib) at the indicated concentrations and
stimulated by the addition of either opsonized zymosan
(1 g/1) (o), the phorbol ester 12-O-tetradecanoylphorbol
13-acetate (10~6 mol/1) (V), or Hank's balanced salt
solution (D). Total counts integrated over 30 min are
presented. The background value without enhancers
was always less than 1000 counts/30 min. Data are the
mean of duplicate cell incubations from one represent-
ative experiment out of three similar ones.
seen at a final blood dilution of 1/100 (fig. 3). Assum-
ing a mean leukocyte count in blood of 5 · 109/1 only
about 12500 leukocytes were present in each well in
a total volume of 250 μΐ.
In routine assays the diluted blood was preincubated
at 31 °C in the luminometer with luminol for 30 min
prior to the stimulation. The simultaneous addition
of enhancer and stimuli resulted in an unchanged total
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Fig. 2. Determination of the most suitable stimulus concentra-
tion for whole blood chemiluminescence. Diluted blood
(1/100) was preincubated with luminol (4 χ 10~4 mol/1)
and stimulated by the addition of either opsonized zym-
osan (Fig. 2a, o) or 12-O-tetradecanoylphorbol 13-ace-
tate (Fig. 2b, V) at the indicated concentrations. Data
are presented as described in fig. 1.
light emission (area under the curve) or maximal
intensity, but the maximum of reactive oxygen species
production was shifted to even earlier time points
(data not shown). It is therefore recommended that
the preincubation time should be held constant (i. e.
30 min) during all experiments.
Influence of different effectors on reactive
oxygen species production in whole blood
In order to further characterize our assay system the
effects of different substances interfering with the
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Fig. 3. Determination of the most suitable blood dilution for
stimulated chemiluminescence measurement. Whole
blood in different dilutions as indicated was preincu-
bated with luminol (4 χ 10~4 mol/1) and stimulated by
the addition of either opsonized zymosan (1 g/1) (o) or
12-O-tetradecanoylphorbol 13-acetate (10~6 mol/1) (V).
Data are presented as described in fig. 1.
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Fig. 4. In vitro drug effects on whole blood chemiluminescence.
Diluted blood (1/100) was preincubated with luminol
(4 χ 10~4 mol/1) and either diclofenac (O) or nordi-
hydroguaiaretic acid (Δ) at the indicated concentrations
as described in Materials and Methods. Stimulation was
achieved by addition of opsonized zymosan (1 g/1). Total
counts integrated over 30 min as the mean from dupli-
cate cell incubations are given.
reactive oxygen species production were investigated.
In these experiments it proved to be absolutely nec-
essary to treat control cells and stimulated cells in an
identical manner. For example, addition of Hank's
balanced salt solution buffer alone led to an up to
tenfold enhancement of total chemiluminescence gen-
eration. In all experiments the effectors were prein-
cubated for 15 min with the diluted whole blood and
the chemical enhancer before stimulus addition and
the start of the 30 min chemiluminescence recording
period. The specific NADPH oxidase inhibitor, di-
phenylene iodonium, effectively diminished light emis-
sion from whole blood. Half maximal inhibition of
basal or opsonized zymosan-induced reactive oxygen
species production was noted at a concentration of
1.5 χ 10~8 mol/1 and no chemiluminescence was re-
corded at a concentration of 1 χ 10 ~6 mol/1. A similar
effect was achieved with sodium azide, which at 10~4
mol/1 nearly totally (90%) blocked reactive oxygen
species production (data not shown). Addition of
Superoxide dismutase (l MU/1) decreased the meas-
ured chemiluminescence less effectively (75% inhibi-
tion). The effects of catalase were very complex in the
whole blood system. At a low catalase concentration
(20 kU/1) the basal and 12-O-tetradecanoylphorbol
13-acetate-stimulated reactive oxygen species produc-
tion was slightly enhanced, whereas at higher concen-
trations of catalase (500-1000 kU/1) a 50% inhibi-
tion of the opsonized zymosan-stimulated chemilu-
minescence was observed (data not shown).
In vitro drug effects on opsonized zymosan-
stimulated reactive oxygen species produc-
tion in whole blood
Using a procedure similar to that described for effec-
tors in the previous section, the direct effects of several
drugs on cellular reactive oxygen species production
can easily be followed with the described chemilumi-
nescence system. In a first attempt the influences of
the antioxidant nordihydroguaiaretic acid and the
non-steroidal antiinflammatory drug diclofenac were
tested. In whole blood the opsonized zymosan-in-
duced light emission was dose-dependently depressed
by both agents with nordihydroguaiaretic acid show-
ing a half maximal inhibition at a concentration of
1.6 χ 10~6 mol/1 and diclofenac at about 1 χ 10~5
mol/1 (fig. 4).
Establishment of reference values for healthy
adults
Under optimal assay conditions blood from 177
healthy donors (124 male and 53 female, age 19 — 63)
was used to establish normal values for basal, opson-
ized zymosan (1 g/1)-, and 12-O-tetradecanoylphorbol
13-acetate (10~6 mol/l)-stimulated chemiluminescence
responses. As can be seen in figure 5, maximal in-
tensities obtained after about 10 min correlated very
well to the total counts (area under curve) obtained
during the whole 30 min incubation time. Therefore,
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 30,1992 / No. 4
Kaever et al.: Whole blood chemiluminescence in microtitre plates 213
1.2
1,0
7/5
0.8
0.6
g 0.4
E
0.2
0.0
5000 10000 15000
Maximum intensity [counts]
20000
1.2
Έ
1
Έ
"c
8 0-8
8*0.6
8
W
S ΟΛΈ
J3
1 0.2
ϋ
0,0
5000 10000 15000
Maximum intensity [counts]
20000
1.2
Ι Ί·°
I 0.8
1
oT 0.6
ΟΛ
1 0.2
0.0
5000 10000 15000
Maximum intensity [counts]
20000
Fig. 5. Correlation between maximum intensity and total
counts integrated over 30 min in whole blood chemil-
uminescence measurement. Determination of whole
blood chemiluminescence was performed under optim-
ized experimental conditions (blood dilution 1/100,
preincubation with 4 χ 10~4 mol/1 luminol, stimulation
with 10~6 mol/1 12-O-tetradecanoylphorbol 13-acetate
or 1 g/1 opsonized zymosan) with samples taken from
\11 healthy adults (124 male and 53 female, age 19-
63). The maximum intensities (observed at about 10 min
after addition of stimulus or vehicle) were correlated to
the total counts (area under curve) integrated over 30
min measuring time. Data are the mean of duplicate
cell incubations.
(fig. 5a, D) basal chemiluminescence, (fig. 5b, V) 12-O-
tetradecanoylphorbol 13-acetate-stimulated chemilumi-
nescence, (fig. 5c, o) opsonized zymosan-stimulated
chemiluminescence.
Tab. 1. Reference values of whole blood chemiluminescence
Leukocytes
Basal chemiluminescence
Area under curve
Area under curve/leukocytes
Minimum
2.9
6.1
0.65
Opsonized zymosan-stimulated chemiluminescence
Area under curve 38.1
Area under curve/leukocytes 4.4
Maximum
14.1
294.0
22.0
588.0
41.8
1 2-O-tetradecanoylphorbol 1 3-acetate-stimulated chemiluminescence
Area under curve 81.8 1 184.0
Area under curve/leukocytes 11.3 64.8
Mean
5.6
51.4
4.1
205.0
14.6
426.0
29.8
S.D.
1.5
43.0
3.1
111.0
1.2
194.0
29.8
CV
26.8
14.9
16Λ
54.1
49.1
45.5
32.9
Whole blood chemiluminescence measurement was performed with samples from \11 healthy adults as specified in figure 5.
Area under curve, 103 counts, Leukocytes, 109/1, CV = coefficient of variation.
further data (tab. 1) were calculated on the basis of
the total count determinations. Although there was a
large range of light emission, especially in the control
cells (treated with Hank's balanced salt solution), a
pronounced stimulation of reactive oxygen species
production was achieved either by the addition of 12-
O-tetradecanoylphorbol 13-acetate (mean 3.6 fold) or
opsonized zymosan (mean ΊΑ fold). When chemilu-
minescence values were corrected for leukocyte count
(tab. 1, area under curve/leukocytes), the deviation of
the opsonized zymosan stimulation was clearly di-
minished from 45.5 to 32.9%. No correlation was
found between chemiluminescence values and either
the age of the donors or the haemoglobin content of
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the blood samples (data not shown). It has to be
noted, however, that only adult blood donors were
included in this experimental series and the haemo-
globin concentrations were quite similar within the
blood samples (120 — 160 g/1). There was also no
significant difference in the chemiluminescence values
between males and females (data not shown).
Discussion
Measurement of whole blood chemiluminescence was
first described more than ten years ago by Kato et al.,
who believed that chemiluminescence determination
in unfractionated whole blood would become a val-
uable method for clinical routine diagnosis (11). It
seems reasonable that whole blood chemiluminesc-
ence provoked by particulate or soluble stimuli is
directly correlated with the activation stage of human
phagocytes and, therefore, represents an early indi-
cator of the progression of different pathophysiolog-
ical situations. In addition, it may be used as an
effective screening system for drugs that either directly
interfere with the phagocyte oxidative burst or exert
immunomodulatory effects. The availability of mod-
ern luminometers allowing the simultaneous chemil-
uminescence detection and computerization from sev-
eral samples has led to a revival of this methodological
approach in recent years (12 — 15). It was the aim of
this study to provide evidence that a sensitive 96-well
luminometer can be also used for this purpose.
It has always been a matter of debate whether chemi-
luminescence measurements should be performed with
whole blood or isolated blood cells. It is incontestable
that reactive oxygen species production strongly de-
pends on the presence and distribution of granulo-
cytes and monocytes in different blood samples and
that various blood components, especially erythro-
cytes (16), interfere with the light emission. In order
to minimize such interferences highly diluted blood
should be used. In our assay system a final 100-fold
dilution (corresponding to 2.5 μΐ blood per well) re-
sulted in optimum light emission, and higher dilutions
with only a few thousand cells per well were also
possible. On the other hand, the isolation of mono-
nuclear or polymorphonuclear leukocytes requires
time-consuming centrifugation steps, which may lead
to preactivation of the cells. The commonly performed
lysis of remaining erythrocytes is also difficult to
standardize. From these considerations it seems pref-
erable to use whole blood in clinical routine assays
and isolated phagocytes in more detailed studies.
Based on our previous observation that whole blood
chemiluminescence measurement is practicable in 96-
well microtitre plates (8) we first determined the op-
timum assay conditions and the effects of several
agents known to influence the production of reactive
oxygen species. It is well documented that activation
of the phagocyte NADPH oxidase by various stimuli
is associated with increased oxygen consumption, an-
aerobic glycolysis via the hexose monophosphate
shunt, and production of reactive oxygen species (17).
In the presence of myeloperoxidase, hydrogen per-
oxide formed from the Superoxide anion radical can
be converted to strongly bactericidal halides. In nor-
mal blood, the numbers of granulocytes greatly exceed
those of other reactive oxygen species-producing cells.
It is therefore assumed that whole blood chemilumi-
nescence predominantly depends on the neutrophil
myeloperoxidase-H2O2-halide system (12). This cor-
relates well with our observation that chemiluminesc-
ence amplification by lucigenin, which more specifi-
cally reacts with O2~ (18), results in a significantly
lower light emission than enhancement by luminol,
which may be a better bystander substrate for other
reactive oxygen species besides Oi~. Addition of di-
phenylene iodonium, a specific inhibitor of the
NADPH oxidase (19), totally blocked reactive oxygen
species production at very low concentrations. Al-
though sodium azide is known to have no influence
on lucigenin-enhanced chemiluminescence from iso-
lated neutrophils (18), in our hands it inhibited the
luminol-amplified chemiluminescence from opsonized
zymosan-stimulated whole blood. This again empha-
sizes the importance of the myeloperoxidase system,
which is inactivated by azide (12, 20). The addition
of Superoxide dismutase or catalase resulted in either
a less effective chemiluminescence decrease, or in more
complex effects reflecting the presence of several en-
zyme systems involved in the reactive oxygen species
production in whole blood. Taken together, the results
obtained with the 96-well microtitre plate system used
in the present study are comparable to those obtained
with conventional 1- or 6-channel luminometers
(12-15).
The described assay system seems well-suited for the
screening of drug effects on cellular reactive oxygen
species production. This holds true for changes in-
duced in vivo or in vitro by biological response mod-
ifiers (8), or even more so for the determination of
direct drug effects on blood cells, as demonstrated in
our study by experiments with the antioxidant, nor-
dihydroguaiaretic acid, or the non-steroidal antiin-
flammatory drug, diclofenac. Compared with other
luminometer systems the outstanding advantage de-
pends on the fact that the effects of several drugs in
different concentrations can be simultaneously deter-
mined in the same blood sample. In addition, only
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250 μΐ blood are needed for an assay of 96 samples
in one microtitre plate. Meanwhile, we have studied
the effects of a broad series of phosphodiesterase
inhibitors on whole blood chemiluminescence gener-
ation (data will be reported separately). The same
advantages are also evident when isolated cells are
used for such studies, although whole blood chemi-
luminescence most probably better agrees with in vivo
conditions. It should be noted that in detailed exper-
iments the drug effects should also be tested in a cell-
free system (i. e. Oi~ production by xanthine/xanthine
oxidase) in order to estimate unspecific scavenging of
reactive oxygen species.
In addition to drug screening, whole blood chemilu-
minescence measurements have been performed in
numerous clinical studies dealing with the evaluation
of congenital phagocyte disorders such as chronic
granulomatous disease or various pathophysiological
situations. Furthermore, an enhanced release of re-
active oxygen species from leukocytes may be one
important pathogenic factor in asthma, psoriasis, and
other inflammatory reactions, acute respiratory dis-
tress syndrome, multiple organ failure, and myocar-
dial infarction. It can be assumed that pathophysiol-
ogical situations involving especially granulocytes can
be followed up by monitoring whole blood chemilu-
minescence. In diseases in which mainly mononuclear
leukocytes play a predominant role no changes in
whole blood chemiluminescence may be expected.
Especially in the febrile period during a bacterial
infection reactive oxygen species production is mark-
edly increased and, therefore, whole blood chemilu-
minescence measurement may provide an early clini-
cal indicator in sepsis. However, we believe that it is
not advisable to determine blood samples from many
different patients with various infections, as the nec-
essary controls before the onset of the infection are
often lacking. It seems more promising to monitor
the progress of the infection and the effect of thera-
peutic intervention in well-defined clinical situations.
Our first study addressing the establishment of normal
values for whole blood chemiluminescence from
healthy adults has clearly shown, in accordance with
other investigations (12, 14, 15), a high degree of
interindividual variation, although blood was only
stored for short periods before the assay (13), and
correction factors for leukocyte counts and the hae-
moglobin content were used (13). In our hands no
significant difference between samples from males and
females was obvious. In preliminary experiments we
found that capillary blood could also be used for
whole blood chemiluminescence measurements, and
the results were similar to those obtained with venous
blood. For this purpose a microtitre plate lumino-
meter offers the advantage that samples from several
patients can be measured in a short time. In addition,
the effects of different stimuli (opsonized zymosan,
12-O-tetradecanoylphorbol 13-acetate, but also com-
plement factors, chemotactic peptides, and cytokines)
in various concentrations can be simultaneously de-
termined, which provides additional data for the as-
sessment and further management of the respective
pathophysiological situation. We have now started a
new clinical study, in which chemiluminescence is
measured in arterial and venous whole blood from
patients after heart transplantation.
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